Nuclear Medicine

Director of Nuclear Medicine at the Westwood and Santa Monica UCLA Hospitals, and Professor in Nuclear Medicine. Dr. Auerbach received his MD degree from the Medical University of Vienna, Austria, and began his career at UCLA with a Research Fellowship, moving into Nuclear Medicine in 2002.

Assistant Professor of UCLA Department of Molecular and Medical Pharmacology, Ahmanson Translational Imaging Division. Dr. Bahri received his medical degree from the University of Goettingen, Germany in 2002. He subsequently started training in the Department of Radiology in Goettingen before relocating to Irvine, CA where he became an Associate Project Scientist at UC Irvine, Center for Functional Onco-Imaging. 

Assistant Professor at the Ahmanson Translational Imaging Division of the Department of Molecular and Medical Pharmacology. Dr. Benz received his MD degree from the Technical University of Munich (Germany) in 2007. He completed his Radiology and Nuclear Medicine residency at the University Hospital of Basel (Switzerland). 

Associate Professor at the Ahmanson Translational Imaging Division, department of Molecular and Medical Pharmacology. Dr. Calais received his MD degree from the University of Paris-Diderot in 2010. He trained in nuclear medicine and cancer imaging at the Henri Becquerel Cancer Center, University of Rouen and board certified by the French Society of Nuclear Medicine in 2014. He received his PhD in Medical Physics and Imaging from the Institut Curie, University Paris-Saclay (France) in 2023.

Professor and Vice Chair of the UCLA Department of Molecular and Medical Pharmacology and Chief of the Ahmanson Translational Imaging. He received his MD degree from the University of Vienna, Austria, and started his career at UCLA as a postdoctoral fellow in Dr. Heinrich Schelbert’s lab. Dr. Czernin’s work focuses on improving the outcomes of cancer patients by developing novel diagnostic and therapeutic approaches.

Associate Professor in the Department of Molecular and Medical Pharmacology and Medical Director of Nuclear Medicine at Santa Monica. Dr. Gupta completed Nuclear Medicine residency training at Cedars Sinai Medical Center before joining UCLA in 2011. Dr. Gupta’s research includes investigating the role of molecular imaging in diagnosing and monitoring treatment response in various cancers. He is also actively involved with clinical theranostic program at UCLA. 

Assistant Professor at the UCLA Ahmanson Translational Theranostics Division of the Department of Molecular and Medical Pharmacology. Dr. Lückerath is a biomedical scientist who obtained her PhD at the Institute for Tumor Biology and Experimental Therapy (Georg-Speyer-Haus, Frankfurt a. M., Germany). She served as head of the research group Experimental Oncology in Nuclear Medicine at the University of Würzurg (Germany) before transferring to UCLA.

Assistant Professor at the UCLA Ahmanson Translational Theranostic Division (ATTD). Dr. Christine Mona received her Ph.D. in Pharmacology in 2016 from Université de Sherbrooke. She joined UCLA in 2016 as a Post-Doctoral Research Associate in Nuclear Medicine in the research group of Professor Johannes Czernin.

Professor in the Department of Pharmacology, Division of Nuclear Medicine, and is the Medical Director of the Clinical PET/CT Program at UCLA. Dr. Quon received his medical degree from the University of Texas, Southwestern Medical School at Dallas and completed this residency and fellowship training at UCLA. Dr. Quon's focus is on radionuclide-based imaging and therapy for malignancy with particular emphasis on lymphoma, neuroendocrine tumors and prostate cancers.

Assistant Professor in Residence in the Department of Molecular and Medical Pharmacology and the Institute of Urologic Oncology. Dr. Ulmert obtained his medical degree at Lund University in Sweden. He began a Postdoctoral Fellowship at Memorial Sloan Kettering in 2010 and has served as a Senior Research Scientist in the Medical Pharmacology Program and as the Technical Director for the Ludwig Center for Cancer Immunotherapy since 2014.